Mazar Andrew Paul 4

What Happened
Andrew Mazar, Chief Operating Officer of Actuate Therapeutics (ACTU), received a grant of 105,000 derivative shares (reported as a $0.00 acquisition) on April 1, 2026. The award is a grant of options that do not require cash payment at grant; value will depend on future stock performance and vesting.

Key Details

• Transaction date: 2026-04-01; filing date: 2026-04-01 (timely filing).
• Grant: 105,000 derivative shares reported at $0.00 per share (reported as an award/grant).
• Vesting (per footnote): 25% vests on April 1, 2027; remaining 75% vests in equal monthly installments over the 36 months following the first anniversary.
• Shares owned after transaction: not specified in the provided filing details.
• No 10b5-1, tax-withholding, cashless exercise, or sale noted in the provided information.

Context
This is an equity compensation grant (stock options) intended for executive retention/incentive and is not an immediate market purchase or sale. Such awards vest over time and only convert to exercisable shares per the schedule above; they do not necessarily indicate near-term buying or selling by the insider.